Liver cancer is a malignant tumor that often shows no warning signs until it is advanced. This is because most liver cancers develop silently from cirrhosis.
Globally, nearly 900,000 people are diagnosed with liver cancer each year. While many cases are identified beyond the early stage, prompt and proper treatment still offers the best possible chance for long-term control and improved outcomes.
China sees nearly half of the world's new liver cancer cases each year. This large volume has built deep clinical experience in managing even the most complex cases.At Fosun Health Greater Bay Area, our hepatobiliary teams use this extensive expertise to treat all types of liver cancer. We provide individualized care for every patient, from early to advanced stages.
Every liver cancer program has surgery, drugs, and radiation. Here is what makes ours different—and why patients from across the region choose Fosun Health:
"My tumor is large, multifocal, or wrapped around major vessels. Surgery is too risky. What else can physically attack the tumor?"
The challenge: Most liver cancers arise in cirrhotic livers that cannot tolerate major surgery. The tumor may be large, multifocal, or wrapped around major vessels. Systemic drugs alone rarely achieve the local control needed to open a curative window.
Our answer: A dual-track interventional platform—all delivered via catheter or needle puncture. No open abdomen. No general anesthesia for the procedure.
Track One: Physical destruction:
When surgery is not the best path, we eliminate the tumor physically—while protecting every gram of healthy liver:
- Image-guided ablation: Radiofrequency (RFA), microwave (MWA), or cryoablation destroys tumor cells with millimeter precision through a needle puncture—leaving every unit of healthy liver intact. No large incisions. No loss of functional liver mass.
- Iodine-125 seeds: Rice-grain-sized radioactive seeds are implanted directly into portal vein/inferior vena cava tumor thrombus, bone metastases, or lymph nodes under image guidance. One procedure, 60–180 days of continuous internal radiation—hitting the thrombus or metastasis from the inside out.
- Tumor hyperthermia: Heating the tumor to 40–43°C disrupts DNA repair and sensitizes cancer cells to radiation and chemotherapy—a force multiplier that makes the same dose work harder, without adding toxicity to the already stressed liver.
Track Two: Conversion therapy:
When the goal is to shrink the tumor toward surgery:
- TACE: Directly blocks the tumor's blood supply via the hepatic artery.
- D-TACE: Microspheres loaded with chemotherapy achieve local drug concentrations 50–100× higher than IV therapy, while sparing the surrounding cirrhotic liver.
- HAIC: Sustained high-concentration regional therapy that "bathes" the tumor over time.
After 1–3 minimally invasive sessions, tumors often shrink significantly—converting initially unresectable disease to a surgical window, while preserving adequate liver function.
What this means for you: In a cirrhotic liver, every gram of functional tissue is precious. Our approach destroys the cancer while protecting what healthy liver you have left. Post-treatment liver function remains nearly as good as before.
"I have portal vein tumor thrombus, or my liver function is too poor for surgery. Is there any curative option left?"
The challenge: Portal vein tumor thrombus (PVTT) or severely impaired liver function often rules out surgery entirely. Conventional radiation risks further damaging the cirrhotic liver, potentially triggering liver failure.
Our answer: Sixth-Generation M6 CyberKnife with real-time tracking and 6D robotic arm technology delivers 0.1mm sub-millimeter precision. The system tracks the liver's respiratory motion and converges radiation from thousands of angles—ablating intrahepatic tumors, postoperative recurrences, or even portal vein tumor thrombus (PVTT) while the surrounding cirrhotic liver receives almost no meaningful dose.
- Intrahepatic tumors or postoperative recurrences: Curative-intent ablation without a scalpel.
- PVTT: Not a dead end. The beam converges on the thrombus while sparing the vessel wall and surrounding liver.
- Poor liver reserve: A genuine radical alternative when surgery is impossible—no anesthesia, no incisions, no bleeding.
What this means for you: PVTT is not a death sentence. In 1–5 non-invasive sessions, CyberKnife provides a curative-intent, organ-preserving option when surgery is impossible—without compromising the fragile liver you have left.
The challenge: In a cirrhotic liver, major resection can push the patient into liver failure. The surgeon must achieve radical tumor clearance while preserving the maximum possible functional liver parenchyma—navigating a field where major veins and arteries weave through scarred, brittle tissue.
Our answer: Robotic-assisted platforms provide 10× magnified 3D vision and wristed instruments with tremor-free micro-precision. In this complex environment, the robot enables true "precision hepatectomy"—removing only the tumor-bearing tissue while meticulously preserving every viable unit of healthy liver, along with the critical vascular and biliary structures.
Less loss of functional liver mass means a dramatically lower risk of postoperative liver failure and a safer path to long-term recovery.
The challenge: Advanced liver cancer requires systemic therapy, but resistance to first-line agents develops predictably. When sorafenib or lenvatinib falter, what comes next?
Our answer: China has emerged as a global leader in liver cancer systemic therapy innovation. Protocols such as camrelizumab (anti-PD-1) combined with apatinib (VEGFR-2 inhibitor) have demonstrated superior survival benefits over sorafenib alone and are endorsed by NCCN, ESMO, and CSCO guidelines. We provide access to fourth-generation targeted agents (for VEGFR, Raf, FGFR) and bispecific antibodies already approved in China—guided by physicians with deep real-world experience in sequencing these therapies through lines of resistance.
Clinical Trial Fast-Track
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Integrative Oncology & TCM
In liver cancer treatment, protecting the liver is not optional—it is the foundation upon which all other therapies rest. Our TCM program functions as a "liver-protecting system optimizer" running parallel to your primary oncological therapy:
Toxicity Reduction: Herbal formulations protect residual liver function, ease chemotherapy-induced nausea and vomiting, reduce cancer-related fatigue, and mitigate myelosuppression. This is particularly critical in cirrhotic patients where liver reserve is already limited.
Efficacy Enhancement: Selected standardized preparations, used alongside interventional or systemic therapy, may improve tumor response rates and support overall treatment tolerance—helping you maintain adequate nutritional status and liver function to complete your full therapeutic course.
Acupuncture provides additional support for pain, nausea, and fatigue. The goal: protect your liver's remaining capacity, reduce treatment burden, and keep you strong enough to finish the fight.
Every liver cancer case at Fosun Health is reviewed by a panel comprising hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, hepatology (liver function specialists), radiology, and pathology experts. This is essential because liver cancer treatment demands constant calibration between oncological aggression and hepatic protection—between removing or destroying the tumor and preserving the organ that must sustain life after treatment.
The MDT convenes within 48 hours of complete documentation.
In February 2024, Mr. Zhang was diagnosed with massive hepatocellular carcinoma in the right liver lobe. He had multiple intrahepatic metastases, combined with tumor thrombus in the left and right branches and the main trunk of the portal vein. The tumor diameter reached a staggering 13.2 x 11.6 cm (AFP positive, PS 2-3, Child-Pugh A, CNLC Stage IIIa). Advanced age, frail condition, and underlying diseases like hypertension and recurrent cholecystitis made the hope for surgery very slim.
2024/02 Liver Cancer (13.2x11.6cm) & Portal Vein Thrombus Before Treatment
After in-depth discussions and comprehensive evaluations with the International Multidisciplinary Team (MDT), Mr. Zhang went through precision radiotherapy combined with targeted therapy and immunotherapy. As time passed, the tumor gradually shrank, the tumor thrombus essentially disappeared, and the abdominal distension symptoms were significantly relieved.
Before & After: The Thrombus virtually disappeared
To further consolidate the treatment effect, Mr. Zhang subsequently underwent Stereotactic Central Ablative Radiotherapy (SCART) targeting the massive primary liver tumor, receiving 3 treatment sessions to achieve further tumor control.
The tumor reduced significantly in 7 months after radiotherapy
Finally, during a follow-up examination in September 2024, the tumor had regressed by 90%, and AFP levels dropped from originally >54,000 ng/ml to within the normal range (3.69 ng/ml).
The left liver showed compensatory hypertrophy, and liver function significantly improved. Mr. Zhang's mental state markedly improved and regained complete self-sufficiency in daily life.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your contrast-enhanced abdominal CT or MRI scans, ultrasound images, liver function tests, tumor marker reports (e.g., AFP), or pathology/biopsy results. Our multidisciplinary liver cancer team will review your case and deliver a preliminary treatment plan with surgical or interventional recommendations within 48 hours.
